Aegerion Pharmaceuticals

company

About

Aegerion Pharmaceuticals engages in the development of therapeutics and pharmaceuticals to treat cardiovascular and metabolic diseases.

  • 101 - 250

Details

Last Funding Type
Convertable Note
Last Funding Money Raised
$3.76M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2005
Number Of Employee
101 - 250
Operating Status
Active

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases.

It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia.

Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$43.86M
Aegerion Pharmaceuticals has raised a total of $43.86M in funding over 2 rounds. Their latest funding was raised on Sep 18, 2008 from a Convertable Note round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 18, 2008 Convertable Note $3.76M 1 Detail
Nov 30, 2007 Series B $17.60M 1 Detail
Jun 13, 2006 Series A $22.50M 1 Advent International Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Aegerion Pharmaceuticals is funded by 1 investors. Advent International are the most recent investors.
Investor Name Lead Investor Funding Round
Advent International Convertable Note